Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

By M. Heinrich, Christopher Corless, C. Blanke, G. Demetri, Heikki Joensuu, P. Roberts, B. Eisenberg, M. von Mehren, C. Fletcher, K. Sandau and 4 more. Journal of Clinical Oncology, 2006

805 citations recorded by the source corpus.

Subfields: Gastroenterology, Surgery

View Paper: https://www.semanticscholar.org/paper/2ec084a176ced9044d20da394fbcf636c447e23e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. J. Fletcher

Citations in the corpus

• Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “Other examples of such gatekeeper mutations include T790 (EGFR) [267], G697R (FLT3) [268], BCR–ABL1 (T315I) [269], PDGFRα (T674I) [270] and KIT (T670I) [271] oncogenic mutations.”
• High-throughput oncogene mutation profiling in human cancer (2007, background): “We found one GIST specimen carrying two KIT mutations, including a D816H mutation recently shown to be associated with resistance to imatini”